Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
atorvast-natrapharm
- Development stage
- Unknown
- Lead developer
- Natrapharm
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Atorvast-Natrapharm is a generic oral film-coated tablet formulation of atorvastatin calcium, a synthetic lipid-lowering agent. It functions as a selective, competitive inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase, the rate-limiting enzyme responsible for converting HMG-CoA to mevalonate during cholesterol biosynthesis in the liver. By reducing hepatic cholesterol levels, the drug triggers an increase in LDL-receptor expression on hepatocyte membranes, which enhances the uptake and clearance of circulating LDL-cholesterol. Marketed by the Filipino company Natrapharm, it is indicated for the management of various lipid disorders, including primary hypercholesterolemia, mixed dyslipidemia, hypertriglyceridemia, and dysbetalipoproteinemia. The medication is manufactured by Apotex in Canada and packaged locally by Lloyd Laboratories.
- Brand names
- Atorvast-Natrapharm
- Other names
- atorvastatin calcium
02
Targets
HMGCR (3-hydroxy-3-methylglutaryl-coenzyme A reductase)
Beyond the preview
Go deeper on atorvast-natrapharm.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on atorvast-natrapharm.